Head-To-Head Contrast: Foghorn Therapeutics (NASDAQ:FHTX) & Praxis Precision Medicines (NASDAQ:PRAX)

Praxis Precision Medicines (NASDAQ:PRAX) and Foghorn Therapeutics (NASDAQ:FHTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Institutional & Insider Ownership

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Praxis Precision Medicines and Foghorn Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

Earnings and Valuation

This table compares Praxis Precision Medicines and Foghorn Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55 million	906.57	-$303.27 million	($12.93)	-21.47
Foghorn Therapeutics	$30.91 million	3.59	-$74.28 million	($0.98)	-1.91

Foghorn Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Praxis Precision Medicines has a beta of 2.85, suggesting that its stock price is 185% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.22, suggesting that its stock price is 222% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Praxis Precision Medicines and Foghorn Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2	0	17	3	2.95
Foghorn Therapeutics	1	6	4	0	2.27

Praxis Precision Medicines presently has a consensus target price of $630.42, suggesting a potential upside of 127.08%. Foghorn Therapeutics has a consensus target price of $6.14, suggesting a potential upside of 228.50%. Given Foghorn Therapeutics’ higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than Praxis Precision Medicines.

Summary

Foghorn Therapeutics beats Praxis Precision Medicines on 9 of the 15 factors compared between the two stocks.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

About Foghorn Therapeutics

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.